| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt","company":"Revium Rx.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_fcc82eef13e42339","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt","content_type":"text/plain","enriched_at":"2026-04-21T10:44:32.855978+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt","source_event_id":"evt_4108e22be954","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"81d7c3cd1d95ac35","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-14","2026-04-20","2026-04-21"],"entities":[{"asset_class":"equity","name":"Revium Rx. Ltd.","relevance":"high","symbol":"","type":"issuer_company"},{"asset_class":"person","name":"Amir Avraham","relevance":"high","symbol":"","type":"individual"},{"asset_class":"equity","name":"Revium Rx Ltd. (Company)","relevance":"high","symbol":"","type":"issuer_company"}],"event_type":"other","information_gaps":["What changed vs prior known state is not provided in the signal; no prior employment terms or earlier filings are included for comparison.","The filing\u2019s SEC 8-K Item(s) and whether other exhibits/material items were included are not shown (material_items is empty).","Exhibit A and Exhibit B contents are referenced but not included in the provided text, so specific leave-day counts and non-competition/proprietary terms are unknown.","The agreement references a \"Commencement Date\" and \"Conf\" (truncated text), but the Commencement Date and any additional terms are not present in the provided excerpt."],"key_facts":["Form 8-K was filed by Revium Rx. (issuer stated as Revium Rx. Ltd.).","The 8-K includes Exhibit 10.1: an Employment Agreement dated April 14, 2026 with an Effective Date of April 14, 2026.","The agreement is between Revium Rx. Ltd. (Israel) and Amir Avraham (ID No. 037690674).","Concurrently with execution, the manager must sign a Proprietary Information, Assignment of Inventions and Non-Competition Agreement attached as Exhibit B.","Vacation/leave: the manager is entitled to leave days per Exhibit A.","Leave accrual limit: if the manager does not utilize leave days, unexploited leave days do not accrue beyond 10 days (\"Accrued Quota\").","Unused leave days exceeding the Accrued Quota may not be redeemed.","Taxes: the manager bears taxes related to payments/benefits; the company may withhold/deduct at source and remit to authorities.","Sexual harassment compliance: manager acknowledges the company\u2019s compliance with relevant regulations and a Prevention of Sexual Harassment Charter (Charter) and undertakes to fulfill its provisions as amended.","Indemnification: the company indemnifies/defends/holds harmless the manager for losses arising from acts/omissions in performing duties/officer capacity, subject to good faith and no intent to derive unlawful personal benefit; also covers the period prior to the Effective Date.","Legal fee advancement: the company advances reasonable legal fees/expenses subject to a customary undertaking to repay if ultimately determined not entitled to indemnification.","D&O insurance: the company maintains directors\u2019 and officers\u2019 liability insurance covering the manager on terms/coverage no less favorable than other senior officers/directors.","Survival: the indemnification/related provisions survive termination of employment.","The agreement includes exhibits: Exhibit A (vacation/leave days) and Exhibit B (Proprietary Information, Assignment of Inventions and Non-Competition Agreement)."],"numeric_claims":[{"label":"Effective date","value":"2026-04-14"},{"label":"Accrued Quota (max unexploited leave days that can accrue)","value":"10 days"}],"primary_claim":"The 8-K filing includes Exhibit 10.1, an employment agreement between Revium Rx. Ltd. and Amir Avraham dated April 14, 2026 (effective date), covering employment terms and manager indemnification/advancement and D&O insurance.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Revium Rx. filed an 8-K that includes an employment agreement (Exhibit 10.1) for Amir Avraham, effective April 14, 2026. The agreement sets employment terms including vacation/leave accrual limits and includes indemnification, legal-fee advancement, and D&O insurance provisions for the manager.","topics":["SEC filing","8-K","employment agreement","indemnification","D&O insurance","vacation/leave accrual","non-competition","proprietary information","sexual harassment prevention"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Revium Rx. \u00b7 Filed 20260420","ticker":"RVRC","tickers":["RVRC"],"title":"RVRC filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-045633.txt"}... |